{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:25:40Z","timestamp":1788013540825,"version":"build-2784847793"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"G\u00fcnter und Regine Kelm Stiftung"},{"name":"Hugo und Elsa Isler-Fonds"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13014-017-0923-8","type":"journal-article","created":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T06:23:38Z","timestamp":1511245418000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["\u201cHEATPAC\u201d - a phase II randomized study of concurrent thermochemoradiotherapy versus chemoradiotherapy alone in locally advanced pancreatic cancer"],"prefix":"10.1186","volume":"12","author":[{"name":"members of the HEATPAC Trial Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloy Ranjan","family":"Datta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Pestalozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Alain","family":"Clavien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Siebenh\u00fcner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emsad","family":"Puric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaka","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Mamot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Riesterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrg","family":"Knuchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e4cilia Sophie","family":"Reiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Bodis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,21]]},"reference":[{"issue":"22","key":"923_CR1","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2016.67.5561","volume":"34","author":"EP Balaban","year":"2016","unstructured":"Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, Javle MM, Eads JR, Allen P, Ko AH, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34(22):2654\u201368.","journal-title":"J Clin Oncol"},{"issue":"17","key":"923_CR2","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1001\/jama.2016.4284","volume":"315","author":"D Schrag","year":"2016","unstructured":"Schrag D. Optimizing treatment for locally advanced pancreas cancer: progress but no precision. JAMA. 2016;315(17):1837\u20138.","journal-title":"JAMA"},{"issue":"2","key":"923_CR3","first-page":"102","volume":"20","author":"E Sawicka","year":"2016","unstructured":"Sawicka E, Mironczuk A, Wojtukiewicz MZ, Sierko E. Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question? Contemp Oncol (Pozn). 2016;20(2):102\u20138.","journal-title":"Contemp Oncol (Pozn)"},{"issue":"17","key":"923_CR4","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","volume":"315","author":"P Hammel","year":"2016","unstructured":"Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouche O, Shannon J, Andre T, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA. 2016;315(17):1844\u201353.","journal-title":"JAMA"},{"issue":"44","key":"923_CR5","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.3748\/wjg.v22.i44.9694","volume":"22","author":"M Ilic","year":"2016","unstructured":"Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22(44):9694\u2013705.","journal-title":"World J Gastroenterol"},{"key":"923_CR6","unstructured":"Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11; Lyon, France International Agency for Research on Cancer; 2013. Available from: \nhttp:\/\/globocan.iarc.fr\n\n. Accessed on June 7, 2017."},{"issue":"8","key":"923_CR7","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4","volume":"48","author":"CG Moertel","year":"1981","unstructured":"Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the gastrointestinal tumor study group. Cancer. 1981;48(8):1705\u201310.","journal-title":"Cancer"},{"issue":"6","key":"923_CR8","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403\u201313.","journal-title":"J Clin Oncol"},{"key":"923_CR9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1186\/1471-2407-14-471","volume":"14","author":"GK Gresham","year":"2014","unstructured":"Gresham GK, Wells GA, Gill S, Cameron C, Jonker DJ. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. BMC Cancer. 2014;14:471.","journal-title":"BMC Cancer"},{"issue":"42","key":"923_CR10","doi-asserted-by":"crossref","first-page":"7461","DOI":"10.3748\/wjg.v19.i42.7461","volume":"19","author":"Y Chen","year":"2013","unstructured":"Chen Y, Sun XJ, Jiang TH, Mao AW. Combined radiochemotherapy in patients with locally advanced pancreatic cancer: a meta-analysis. World J Gastroenterol. 2013;19(42):7461\u201371.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"923_CR11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.pan.2016.01.003","volume":"16","author":"D Ciliberto","year":"2016","unstructured":"Ciliberto D, Staropoli N, Chiellino S, Botta C, Tassone P, Tagliaferri P. Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer. Pancreatology. 2016;16(2):249\u201358.","journal-title":"Pancreatology"},{"issue":"9","key":"923_CR12","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ctrv.2015.05.009","volume":"41","author":"NR Datta","year":"2015","unstructured":"Datta NR, Ordonez SG, Gaipl US, Paulides MM, Crezee H, Gellermann J, Marder D, Puric E, Bodis S. Local hyperthermia combined with radiotherapy and\u2212\/or chemotherapy: recent advances and promises for the future. Cancer Treat Rev. 2015;41(9):742\u201353.","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"923_CR13","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1470-2045(02)00818-5","volume":"3","author":"P Wust","year":"2002","unstructured":"Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, Felix R, Schlag PM. Hyperthermia in combined treatment of cancer. Lancet Oncol. 2002;3(8):487\u201397.","journal-title":"Lancet Oncol."},{"issue":"6","key":"923_CR14","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3109\/02656736.2012.677933","volume":"28","author":"B Frey","year":"2012","unstructured":"Frey B, Weiss EM, Rubner Y, Wunderlich R, Ott OJ, Sauer R, Fietkau R, Gaipl US. Old and new facts about hyperthermia-induced modulations of the immune system. Int J Hyperth. 2012;28(6):528\u201342.","journal-title":"Int J Hyperth"},{"issue":"1","key":"923_CR15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00000421-200302000-00013","volume":"26","author":"S Mose","year":"2003","unstructured":"Mose S, Class R, Weber HW, Rahn A, Brady LW, Bottcher HD. Radiation enhancement by gemcitabine-mediated cell cycle modulations. Am J Clin Oncol. 2003;26(1):60\u20139.","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"923_CR16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1634\/theoncologist.10-1-34","volume":"10","author":"B Pauwels","year":"2005","unstructured":"Pauwels B, Korst AE, Lardon F, Vermorken JB. Combined modality therapy of gemcitabine and radiation. Oncologist. 2005;10(1):34\u201351.","journal-title":"Oncologist"},{"issue":"3","key":"923_CR17","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1080\/02656730802657036","volume":"25","author":"S Adachi","year":"2009","unstructured":"Adachi S, Kokura S, Okayama T, Ishikawa T, Takagi T, Handa O, Naito Y, Yoshikawa T. Effect of hyperthermia combined with gemcitabine on apoptotic cell death in cultured human pancreatic cancer cell lines. Int J Hyperth. 2009;25(3):210\u20139.","journal-title":"Int J Hyperth"},{"issue":"10","key":"923_CR18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00066-011-2226-6","volume":"187","author":"S Maluta","year":"2011","unstructured":"Maluta S, Schaffer M, Pioli F, Dall'oglio S, Pasetto S, Schaffer PM, Weber B, Giri MG. Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer : an open-label comparative cohort trial. Strahlenther Onkol. 2011;187(10):619\u201325.","journal-title":"Strahlenther Onkol"},{"issue":"7","key":"923_CR19","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3109\/02656736.2012.695428","volume":"28","author":"T Ishikawa","year":"2012","unstructured":"Ishikawa T, Kokura S, Sakamoto N, Ando T, Imamoto E, Hattori T, Oyamada H, Yoshinami N, Sakamoto M, Kitagawa K, et al. Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer. Int J Hyperth. 2012;28(7):597\u2013604.","journal-title":"Int J Hyperth"},{"issue":"1","key":"923_CR20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3109\/02656736.2012.740764","volume":"29","author":"KE Tschoep-Lechner","year":"2013","unstructured":"Tschoep-Lechner KE, Milani V, Berger F, Dieterle N, Abdel-Rahman S, Salat C, Issels RD. Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. Int J Hyperth. 2013;29(1):8\u201316.","journal-title":"Int J Hyperth"},{"key":"923_CR21","first-page":"50 (Abs)","volume-title":"The effect of the combination therapy of hyperthermia and gemcitabine for the treatment of advanced inoperable pancreatic cancer","author":"T Takagi","year":"2008","unstructured":"Takagi T, Kokura S, Ishikawa T, Inui T, Isozaki Y, Oyamada H, Ando T, Naito Y, Handa O, Yoshikawa T. The effect of the combination therapy of hyperthermia and gemcitabine for the treatment of advanced inoperable pancreatic cancer. Munich: 10th International Congress on Hyperthermia Oncology; 2008. p. 50 (Abs)."},{"issue":"3","key":"923_CR22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/02656730110108794","volume":"18","author":"VE Kouloulias","year":"2002","unstructured":"Kouloulias VE, Kouvaris JR, Nikita KS, Golematis BC, Uzunoglu NK, Mystakidou K, Papavasiliou C, Vlahos L. Intraoperative hyperthermia in conjunction with multi-schedule chemotherapy (pre-, intra- and post-operative), by-pass surgery, and post-operative radiotherapy for the management of unresectable pancreatic adenocarcinoma. Int J Hyperth. 2002;18(3):233\u201352.","journal-title":"Int J Hyperth"},{"key":"923_CR23","unstructured":"EU Clinical Trials Register: Available from: \nhttps:\/\/www.clinicaltrialsregister.eu\n\n. Accessed on October 18, 2017."},{"key":"923_CR24","unstructured":"Issels RD Hyperthermia European Adjuvant Trial (HEAT). \nClinicalTrials.gov\n\n Identifier: NCT01077427. : 2012. Available from: \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT01077427\n\n. Accessed on June 7, 2017."},{"key":"923_CR25","unstructured":"Datta NR Concurrent Hyperthermia and Chemoradiotherapy in LAPC: Phase II Study (HEATPAC), \nClinicalTrials.gov\n\n Identifier: NCT 02439593. : 2016. Available from: \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02439593\n\n. Accessed on June 7, 2017."},{"issue":"1","key":"923_CR26","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1148\/radiol.13131184","volume":"270","author":"MM Al-Hawary","year":"2014","unstructured":"Al-Hawary MM, Francis IR, Chari ST, Fishman EK, Hough DM, DS L, Macari M, Megibow AJ, Miller FH, Mortele KJ, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American pancreatic association. Radiology. 2014;270(1):248\u201360.","journal-title":"Radiology"},{"issue":"7","key":"923_CR27","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1245\/s10434-009-0408-6","volume":"16","author":"MP Callery","year":"2009","unstructured":"Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1727\u201333.","journal-title":"Ann Surg Oncol"},{"key":"923_CR28","unstructured":"RTOG 0848: A phase IIR and a phase III trial evaluating both erlotinib (Ph IIR) and chemoradiation (Ph III) as adjuvant treatment for patients with resected head of pancreas adenocarcinoma Available from: \nhttps:\/\/www.rtog.org\/ClinicalTrials\/ProtocolTable\/StudyDetails.aspx?study=0848\n\n. Accessed on June 7, 2017."},{"key":"923_CR29","unstructured":"RTOG 1201: A phase II randomized trial of high versus standard intensity local or systemic therapy for unresectable pancreatic cancer: Available from: \nhttps:\/\/www.rtog.org\/ClinicalTrials\/ProtocolTable\/StudyDetails.aspx?study=1201\n\n. Accessed on June 7, 2017."},{"key":"923_CR30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1748-717X-5-28","volume":"5","author":"W Sun","year":"2010","unstructured":"Sun W, Leong CN, Zhang Z, Lu JJ. Proposing the lymphatic target volume for elective radiation therapy for pancreatic cancer: a pooled analysis of clinical evidence. Radiat Oncol. 2010;5:28.","journal-title":"Radiat Oncol"},{"issue":"10","key":"923_CR31","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00066-011-1145-x","volume":"187","author":"G Bruggmoser","year":"2011","unstructured":"Bruggmoser G, Bauchowitz S, Canters R, Crezee H, Ehmann M, Gellermann J, Lamprecht U, Lomax N, Messmer MB, Ott O, et al. Quality assurance for clinical studies in regional deep hyperthermia. Strahlenther Onkol. 2011;187(10):605\u201310.","journal-title":"Strahlenther Onkol"},{"issue":"2","key":"923_CR32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/02656739809018219","volume":"14","author":"JJ Lagendijk","year":"1998","unstructured":"Lagendijk JJ, Van Rhoon GC, Hornsleth SN, Wust P, De Leeuw AC, Schneider CJ, Van Dijk JD, Van Der Zee J, Van Heek-Romanowski R, Rahman SA, et al. ESHO quality assurance guidelines for regional hyperthermia. Int J Hyperth. 1998;14(2):125\u201333.","journal-title":"Int J Hyperth"},{"key":"923_CR33","unstructured":"US Department of Health and Human Services Common terminology criteria for adverse events (CTCAE) version 4.0: Available from: \nhttps:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf\n\n. Accessed on June 7, 2017."},{"issue":"2","key":"923_CR34","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"1","key":"923_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1\u201310.","journal-title":"Control Clin Trials"},{"issue":"5","key":"923_CR36","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.ijrobp.2015.12.361","volume":"94","author":"NR Datta","year":"2016","unstructured":"Datta NR, Puric E, Klingbiel D, Gomez S, Bodis S. Hyperthermia and radiation therapy in locoregional recurrent breast cancers: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2016;94(5):1073\u201387.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"923_CR37","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/02656736.2016.1195924","volume":"32","author":"NR Datta","year":"2016","unstructured":"Datta NR, Rogers S, Klingbiel D, Gomez S, Puric E, Bodis S. Hyperthermia and radiotherapy with or without chemotherapy in locally advanced cervical cancer: a systematic review with conventional and network meta-analyses. Int J Hyperth. 2016;32(7):809\u201321.","journal-title":"Int J Hyperth"},{"issue":"1","key":"923_CR38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/02656736.2015.1099746","volume":"32","author":"NR Datta","year":"2016","unstructured":"Datta NR, Rogers S, Ordonez SG, Puric E, Bodis S. Hyperthermia and radiotherapy in the management of head and neck cancers: a systematic review and meta-analysis. Int J Hyperth. 2016;32(1):31\u201340.","journal-title":"Int J Hyperth"},{"issue":"6","key":"923_CR39","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(10)70071-1","volume":"11","author":"RD Issels","year":"2010","unstructured":"Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem BC, Abdel-Rahman S, Daugaard S, Salat C, Wendtner CM, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010;11(6):561\u201370.","journal-title":"Lancet Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-017-0923-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T06:23:57Z","timestamp":1511245437000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-017-0923-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,21]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["923"],"URL":"https:\/\/doi.org\/10.1186\/s13014-017-0923-8","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,21]]},"article-number":"183"}}